Fo­cused on da­ta and drug de­vel­op­ment, Soft­Bank hunts new $1B biotech deals — re­port

Soft­Bank’s mam­moth $1.1 bil­lion in­vest­ment in Vivek Ra­maswamy’s Roivant Sci­ences won’t like­ly be its last in biotech.

Quot­ing sources fa­mil­iar with the deal, Bloomberg is …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER